TaiMed Biologics Inc.
Taipei Exchange 4147.TWO
TaiMed Biologics Inc. Operating Income for the year ending December 31, 2023: USD -5.41 M
-
TaiMed Biologics Inc. Operating Income for the year ending December 31, 2022 was USD -8.46 M, a 49.43% change year over year.
-
TaiMed Biologics Inc. Operating Income for the year ending December 31, 2021 was USD -16.72 M, a -162.42% change year over year.
-
TaiMed Biologics Inc. Operating Income for the year ending December 31, 2020 was USD -6.37 M, a 67.04% change year over year.
-
TaiMed Biologics Inc. Operating Income for the year ending December 31, 2019 was USD -19.33 M, a -84.30% change year over year.
| Date | Operating Income | EBIT | EBITDA | Net Income |
|---|
| CEO | Mr. Chin-Ming Chang Ph.D. |
| IPO Date | June 20, 2012 |
| Location | Taiwan |
| Headquarters | No. 607, Ruiguang Road |
| Employees | 79 |
| Sector | Health Care |
| Industries | |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Past 5 years
USD 1.70
USD 2.91
StockViz Staff
January 15, 2025
Any question? Send us an email